My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Terazosin HCl dihydrate
    Terazosin HCl dihydrate

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1147
    CAS #: 70024-40-7Purity ≥98%

    Description: Terazosin HCl (Hytrin; A-45975; A45975), the hydrochloride salt ofterazosin, is a potent and selective α1-adrenoceptor antagonist with antihypertensive effects. It has been used for treatment of BPH- benign prostatic hyperplasia (symptoms of an enlarged prostate). Terazosin induces cytotoxicity in PC-3 and human benign prostatic cells with an IC50 of more than 100 μM. Terazosin also effectively inhibited vascular endothelial growth factor induced proliferation and tube formation in cultured human umbilical vein endothelial cells (IC50 9.9 and 6.8 μM, respectively).

    References: Neuroscience. 1999;94(4):1245-52; J Urol. 2003 Feb;169(2):724-9.

    Related CAS#: 63590-64-7 (free base); 63074-08-8 ( Terazocin Hydrochloride);  

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)459.92 
    FormulaC19H25N5O4.HCl.2H2O 
    CAS No.70024-40-7  (Terazosin Hydrochloride dihydrate);
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: > 10 mM
    Water: N/A
    Ethanol: N/A
    Solubility (In vivo)Chemical Name: Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-, monohydrochloride
    InChi Key: IWSWDOUXSCRCKW-UHFFFAOYSA-N
    InChi Code: InChI=1S/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H
    SMILES Code: O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4OCCC4.[H]Cl
    SynonymsTerazosin hydrochloride; Hytrin; A-45975; A45975; Terazosin HCl hydrate; A 45975; Terazosin HCl dihydrate


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Terazosin induces cytotoxicity in PC-3 and human benign prostatic cells with an IC50 of more than 100 μM. Terazosin also effectively inhibited vascular endothelial growth factor induced proliferation and tube formation in cultured human umbilical vein endothelial cells (IC50 9.9 and 6.8 μM, respectively).


    Cell Assay: To determine the cytotoxic effect mode of action, several identification techniques were used in the current study. Apoptotic cells are detected in situ using terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling. Results show a positive reaction after a 12-hour treatment of PC-3 cells with terazosin (100 μM).

    In VivoTerazosin produces a dose-dependent, complete inhibition of motor activity and catalepsy. Intraventricularly administered this antagonist protects striatal and cerebral cortical alpha 1 receptors but not striatal or cortical D1 receptors from in vivo alkylation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroxyquinoline. Intraventricular terazosin also produces hypothermia and a reduced respiratory rate suggestive of a reduced sympathetic outflow. Terazosin does not impair performance on a horizontal wire test or the ability to make coordinated movements in a swim test. Terazosin significantly inhibits vascular endothelial growth factor induced angiogenesis in nude mice with an IC50 of 7.9 μM, showing that it has a more potent anti-angiogenic than cytotoxic effect. 
    Animal modelMice 
    Formulation & DosageDissolved in water; 0.05 mg/kg; oral gavage 
    ReferencesNeuroscience. 1999;94(4):1245-52; J Urol. 2003 Feb;169(2):724-9. 


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Terazosin HCl dihydrateRepresentative traces of urethral (a) and abdominal (b) pressure changes induced by duloxetine (1 mg/kg iv) in the presence of intrathecal (it) methiothepin maleate (A), terazosin (B), coapplication of methiothepin maleate and terazosin (C), and coapplication. Am J Physiol Renal Physiol. 2008 Jul; 295(1): F264–F271.
     
    Terazosin HCl dihydrate
    (a) Emission spectra obtained for 8 standard solutions of terazosin with different concentrations. (b) Emission spectrum of terazosin (75 μg L−1) treated the same as previously described in the general analytical procedure. Int J Anal Chem. 2012; 2012: 546282.
     
    Terazosin HCl dihydrate
    Influence of NaPF6 on the analytical signals obtained for terazosin.


    Terazosin HCl dihydrate
    Influence of amount of [Hpy][PF6] on the fluorescence intensities. Int J Anal Chem. 2012; 2012: 


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?